NO20076628L - Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser - Google Patents

Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser

Info

Publication number
NO20076628L
NO20076628L NO20076628A NO20076628A NO20076628L NO 20076628 L NO20076628 L NO 20076628L NO 20076628 A NO20076628 A NO 20076628A NO 20076628 A NO20076628 A NO 20076628A NO 20076628 L NO20076628 L NO 20076628L
Authority
NO
Norway
Prior art keywords
ziprasidone
controlled release
nanoparticulate compositions
composition
schizophrenia
Prior art date
Application number
NO20076628A
Other languages
English (en)
Inventor
Gurvinder Singh Rekhi
Gary Liversidge
Scott Jenkins
John Devane
Niall Fanning
Paul Stark
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/372,857 external-priority patent/US20060240105A1/en
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20076628L publication Critical patent/NO20076628L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer en sammensetning som omfatter ziprasidon som er nyttig til behandling eller forhindring av schizofreni og lignende psykiatriske lidelser. I en utforming omfatter sammensetningen nanopartikler som omfatter ziprasidon og minst én overflatestabilisator. Nanopartikkelpartiklene har en effektiv gjennomsnittlig partikkelstørrelse på mindre enn omtrent 200 nm. I en annen utforming omfatter sammensetningen en modifisert frigjøringssammensetning som ved administrering til en pasient leverer ziprasidon på en bimodal, multimodal eller kontinuerlig måte. Oppfinnelsen angår også doseringsformer som inneholder slike sammensetninger og fremgangsmåter til behandling og forhindring av schizofreni og lignende psykiatriske lidelser.
NO20076628A 2005-06-20 2007-12-21 Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser NO20076628L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69209605P 2005-06-20 2005-06-20
US11/372,857 US20060240105A1 (en) 1998-11-02 2006-03-10 Multiparticulate modified release composition
PCT/US2006/023695 WO2007027273A1 (en) 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Publications (1)

Publication Number Publication Date
NO20076628L true NO20076628L (no) 2008-03-12

Family

ID=37809174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076628A NO20076628L (no) 2005-06-20 2007-12-21 Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser

Country Status (12)

Country Link
EP (1) EP1901722A4 (no)
KR (1) KR20080024206A (no)
CN (1) CN101879140A (no)
AU (1) AU2006285349A1 (no)
BR (1) BRPI0612297A2 (no)
CA (1) CA2613474A1 (no)
EA (1) EA200800092A1 (no)
HK (1) HK1117060A1 (no)
IL (1) IL188093A0 (no)
NO (1) NO20076628L (no)
SG (1) SG162811A1 (no)
WO (1) WO2007027273A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014910A (zh) * 2008-03-07 2011-04-13 美国辉瑞有限公司 在无食物条件下施用齐拉西酮的方法、剂型和试剂盒
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
CN106061292B (zh) 2013-12-16 2020-01-21 麻省理工学院 强化的微量营养素盐调配物
AU2014364930B2 (en) 2013-12-16 2017-06-15 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
DE69939748D1 (de) * 1998-11-02 2008-11-27 Elan Pharma Int Ltd Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
SI1181018T1 (en) * 1999-05-27 2003-06-30 Pfizer Products Inc. Ziprasidone suspension
JP2006514923A (ja) * 2002-10-25 2006-05-18 ファイザー・プロダクツ・インク 注射可能な新規なデポ製剤
EP1663166A2 (en) * 2003-09-02 2006-06-07 Imran Ahmed Sustained release dosage forms of ziprasidone
BRPI0609299A2 (pt) * 2005-04-13 2010-03-23 Pfizer Prod Inc formulaÇÕes de depàsito injetÁveis e mÉtodos para proporcionar liberaÇço sustentada de composiÇÕes de nanopartÍculas

Also Published As

Publication number Publication date
CA2613474A1 (en) 2007-03-08
AU2006285349A1 (en) 2007-03-08
CN101879140A (zh) 2010-11-10
HK1117060A1 (en) 2009-01-09
BRPI0612297A2 (pt) 2010-11-03
EP1901722A1 (en) 2008-03-26
EA200800092A1 (ru) 2008-06-30
EP1901722A4 (en) 2011-06-15
IL188093A0 (en) 2008-03-20
KR20080024206A (ko) 2008-03-17
SG162811A1 (en) 2010-07-29
WO2007027273A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
NO20073289L (no) Nanopartikkelsammensetninger med kontrollert frigjoring som omfatter cephalosporin
NO20076628L (no) Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser
NO20080202L (no) Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer
NO20076692L (no) Nanopartikulaere acetaminofenformuleringer
ATE431131T1 (de) Meloxican-formulierungen in nanoteilchenform
SG170047A1 (en) Nanoparticulate posaconazole formulations
NO20076215L (no) Nanopartikulaere clopidogrelformuleringer
WO2007035348A3 (en) Nanoparticulate aripiprazole formulations
WO2006110809A3 (en) Nanoparticulate lipase inhibitor formulations
SG161203A1 (en) Nanoparticulate tacrolimus formulations
WO2008089310A3 (en) Delta 5 desaturase inhibitors for the treatment of obesity
EA200702641A1 (ru) Препараты наночастиц мезилата иматиниба
NO20076588L (no) Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring
ATE457718T1 (de) Sterile gefilterte nanoteilchen-formulierungen von budesonid mit tyloxapol als oberflächenstabilisator
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
NO20073334L (no) Nanopartikulaert benzotiofenformuleringer
NO20090379L (no) Nanopartikulaere formuleringer av modafinil
JP2008538751A5 (no)
WO2006135689A3 (en) Nanoparticulate ebastine formulations
MX341329B (es) Sistema de nanoparticulas, proceso para la preparacion de las mismas, uso de las mismas, composicion fotoprotectora, proceso para la preparacion de la misma, y metodo de prevencion de enfermedades de la piel.
WO2006138421A3 (en) Nanoparticulate azelnidipine formulations
BRPI0614080A2 (pt) Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения
GB2442366A (en) Nanoparticulate and controlled release compositions comprising prostaglandin derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application